Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer’s disease using a single blood test. In a study published in Nature Medicine, the researchers demonstrated that their models predicted the onset of Alzheimer’s symptoms within a margin of three to four years.
NG Biotech manufactured the assays in France, with Hardy Diagnostics serving as the exclusive distributor in the US.
Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a score that predicts the risk of liver cancer. Published in the journal Proceedings of the National Academy of Sciences, the study establishes that the protein MYCN drives liver tumorigenesis, specifically of the type of tumors found in the deadliest subtype of liver cancer.
A traditional Chinese mind-body practice that combines slow, structured movement, deep breathing and meditative focus lowered blood pressure as effectively as brisk walking in a large randomized clinical trial published in JACC. Blood pressure reductions were seen after three months and sustained for one year.
WESTFIELD, Ind., Feb. 17, 2026 /PRNewswire/ — Today, Portal Diabetes, Inc. (“Portal”) announced its receipt of the Breakthrough Device Designation by the Food and Drug Administration (FDA) for its implantable insulin pump system called “Portal Pump,” and the start of a Phase 1 study on its proprietary temperature-stable insulin (“Portal Insulin”).
MURRIETA, Calif., Feb. 17, 2026 /PRNewswire/ — Copan Group announced today that PhenoMATRIX®, its automated image assessment software used with WASPLab® full laboratory automation, received FDA 510(k) clearance as a Class II device in the United States.
St. Jude Children’s Research Hospital scientists, in collaboration with scientists at the Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and other international centers, created Methylation-based Predictive Algorithm for CNS Tumors (M-PACT). M-PACT uses AI to sift through ctDNA in cerebrospinal fluid and molecularly classify tumors based on their DNA methylation pattern.
UCLA researchers have developed a lipid nanoparticle-based gene-editing approach capable of inserting an entire healthy gene into human airway cells, restoring key biological function in a laboratory model of cystic fibrosis and establishing a potential new path toward mutation-agnostic gene therapy for inherited lung diseases.
Researchers at The University of Texas MD Anderson Cancer Center have developed a new computational approach designed to better account for changes in gene expression within tumors relative to their unique microenvironments. This approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast cancer (TNBC).
In two new studies on 28,000 individuals, researchers are able to show that genetic variants in 11 regions of the human genome have a clear influence on which bacteria are in the gut and what they do there. Only two genetic regions were previously known. Some of the new genetic variants can be linked to an increased risk of gluten intolerance, hemorrhoids and cardiovascular diseases.